Dipraglurant (ADX48621) is primarily investigated for its potential therapeutic applications in neurological disorders. It is a selective antagonist of the metabotropic glutamate receptor 5 (mGluR5), which plays a significant role in modulating synaptic transmission and plasticity in the brain. This makes it a promising candidate for treating conditions like Parkinson’s disease, particularly in addressing levodopa-induced dyskinesia (LID), a common side effect of long-term Parkinson’s treatment. By targeting mGluR5, it helps regulate abnormal glutamate signaling, which is implicated in the development of dyskinesias. Additionally, its application is being explored in other neurological and psychiatric disorders, such as anxiety, Fragile X syndrome, and addiction, where mGluR5 modulation may offer therapeutic benefits. Research continues to evaluate its efficacy and safety in clinical settings.